{"id":400507,"date":"2020-12-15T17:20:16","date_gmt":"2020-12-15T22:20:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400507"},"modified":"2020-12-15T17:20:16","modified_gmt":"2020-12-15T22:20:16","slug":"shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/","title":{"rendered":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc."},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">Dec. 15, 2020<\/span> \/PRNewswire\/ &#8212; <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3014084-4&amp;h=1284488111&amp;u=http%3A%2F%2Fweisslawllp.com%2F&amp;a=WeissLaw+LLP\" rel=\"nofollow noopener noreferrer\">WeissLaw LLP<\/a>\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Prevail Therapeutics Inc. (&#8220;Prevail&#8221; or the &#8220;Company&#8221;) (NASDAQ: PRVL) in connection with the proposed acquisition of the Company by Eli Lilly and Company. \u00a0Under the terms of the acquisition agreement, the Company&#8217;s shareholders will only receive <span class=\"xn-money\">$22.50<\/span> per share in cash for each share of Prevail common stock that they hold.\u00a0 Additionally, Prevail shareholders will be entitled to receive a contingent value right worth up to <span class=\"xn-money\">$4.00<\/span> per share in cash, to be paid subject to certain terms and conditions upon the first regulatory approval for commercial sale of a Prevail product in one of the following countries: <span class=\"xn-location\">United States<\/span>, <span class=\"xn-location\">Japan<\/span>, <span class=\"xn-location\">United Kingdom<\/span>, <span class=\"xn-location\">Germany<\/span>, <span class=\"xn-location\">France<\/span>, <span class=\"xn-location\">Italy<\/span> or <span class=\"xn-location\">Spain<\/span>. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\" title=\"WeissLaw LLP (PRNewsfoto\/WeissLaw LLP)\" alt=\"WeissLaw LLP (PRNewsfoto\/WeissLaw LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p class=\"prntac\">\n        <b><br \/>\n          <u>If you own Prevail shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:<\/u><br \/>\n        <\/b>\n      <\/p>\n<p class=\"prntac\">\n        <b><br \/>\n          <a href=\"https:\/\/www.weisslawllp.com\/prvl\/\" rel=\"nofollow\">https:\/\/www.weisslawllp.com\/prvl\/<\/a><br \/>\n        <\/b>\n      <\/p>\n<p class=\"prntac\">\n        <b><br \/>\n          <u>Or please contact:<\/u><br \/>\n        <\/b><br \/>\n        <br \/>\n        <b><br \/>\n          <span class=\"xn-person\">Joshua Rubin, Esq.<\/span><br \/>\n          <br \/>\n        <\/b>WeissLaw LLP<br \/>1500 Broadway, 16<sup>th<\/sup> Floor<br \/><span class=\"xn-location\">New York<\/span>, NY\u00a0 10036<br \/><b>(212)\u00a0682-3025<\/b><br \/><b>(888) 593-4771<br \/><a href=\"mailto:stockinfo@weisslawllp.com\" rel=\"nofollow\">stockinfo@weisslawllp.com<\/a><\/b><\/p>\n<p>WeissLaw is investigating whether (i) Prevail&#8217;s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Prevail&#8217;s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.\u00a0 <\/p>\n<p>WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.\u00a0 We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.\u00a0 If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at <b><a href=\"mailto:stockinfo@weisslawllp.com\" rel=\"nofollow\">stockinfo@weisslawllp.com<\/a><\/b><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC25175&amp;sd=2020-12-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc-301193539.html\">http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc-301193539.html<\/a><\/p>\n<p>SOURCE  WeissLaw LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC25175&amp;Transmission_Id=202012151717PR_NEWS_USPR_____DC25175&amp;DateId=20201215\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ &#8212; WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Prevail Therapeutics Inc. (&#8220;Prevail&#8221; or the &#8220;Company&#8221;) (NASDAQ: PRVL) in connection with the proposed acquisition of the Company by Eli Lilly and Company. \u00a0Under the terms of the acquisition agreement, the Company&#8217;s shareholders will only receive $22.50 per share in cash for each share of Prevail common stock that they hold.\u00a0 Additionally, Prevail shareholders will be entitled to receive a contingent value right worth up to $4.00 per share in cash, to be paid subject to certain terms and conditions upon the first regulatory approval for commercial sale of a Prevail product &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400507","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ &#8212; WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Prevail Therapeutics Inc. (&#8220;Prevail&#8221; or the &#8220;Company&#8221;) (NASDAQ: PRVL) in connection with the proposed acquisition of the Company by Eli Lilly and Company. \u00a0Under the terms of the acquisition agreement, the Company&#8217;s shareholders will only receive $22.50 per share in cash for each share of Prevail common stock that they hold.\u00a0 Additionally, Prevail shareholders will be entitled to receive a contingent value right worth up to $4.00 per share in cash, to be paid subject to certain terms and conditions upon the first regulatory approval for commercial sale of a Prevail product &hellip; Continue reading &quot;SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T22:20:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc.\",\"datePublished\":\"2020-12-15T22:20:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/\"},\"wordCount\":345,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/\",\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"datePublished\":\"2020-12-15T22:20:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc. - Market Newsdesk","og_description":"PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ &#8212; WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Prevail Therapeutics Inc. (&#8220;Prevail&#8221; or the &#8220;Company&#8221;) (NASDAQ: PRVL) in connection with the proposed acquisition of the Company by Eli Lilly and Company. \u00a0Under the terms of the acquisition agreement, the Company&#8217;s shareholders will only receive $22.50 per share in cash for each share of Prevail common stock that they hold.\u00a0 Additionally, Prevail shareholders will be entitled to receive a contingent value right worth up to $4.00 per share in cash, to be paid subject to certain terms and conditions upon the first regulatory approval for commercial sale of a Prevail product &hellip; Continue reading \"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T22:20:16+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc.","datePublished":"2020-12-15T22:20:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/"},"wordCount":345,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/","name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","datePublished":"2020-12-15T22:20:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-prevail-therapeutics-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Prevail Therapeutics Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400507"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400507\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}